L 657743

Subscribe to Selected New Research on L 657743

8 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: structure given in first source

Also Known As:

1',3'-dimethylspiro(1,3,4,5',6,6',7,12b-octahydro-2H-benzo(b)furo(2,3-a)quinolizine)-2,4'-pyrimidin-2'-one; L 657,743; L-657,743; L-657,743-002W; MK 912; MK-912

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Quinolizines: 1

L 657743: 8

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 11/01/1991 - "Ten asymptomatic patients with NIDDM received either a single oral dose of MK-912 (2 mg) or placebo in a double-blind, cross-over study" 11/01/1991 - "We used MK-912, a potent new selective alpha 2-adrenergic receptor antagonist that is active orally, to study the effect of short-term, selective alpha 2-blockade on fasting plasma glucose (FPG) and pancreatic islet function in non-insulin-dependent diabetes (NIDDM)" Get all the results and reference details, order at left...
2.	Mydriasis 04/01/1988 - "In tests carried out in vivo with rats for ascertaining alpha-2 adrenoceptor antagonism in the central nervous system--namely, accumulation of cortical dopa and antagonism of mydriasis induced by the alpha-2 agonist, clonidine--L-659,066 had, respectively, less than 1/345th and about 1/5000th of the potency of L-657,743" 08/01/1987 - "In vivo, L-657,743 potently blocked clonidine-induced mydriasis in the rat and stimulated cerebrocortical norepinephrine synthesis, two indices of central alpha 2-adrenoceptor antagonism" Get all the results and reference details, order at left...
3.	Hypotension (Low Blood Pressure) 07/01/2002 - "RESULTS: MK-912 and idazoxan dose-dependently reversed both clonidine and guanfacine-induced cognitive improvement and hypotension" 07/01/1989 - "The 2 mg dose of MK-912 significantly inhibited the clonidine-induced hypotension, bradycardia, xerostomia, and increase in plasma glucose concentrations that were observed during the placebo treatment period (p less than 0.05)" Get all the results and reference details, order at left...
4.	Xerostomia 07/01/1989 - "The 2 mg dose of MK-912 significantly inhibited the clonidine-induced hypotension, bradycardia, xerostomia, and increase in plasma glucose concentrations that were observed during the placebo treatment period (p less than 0.05)" Get all the results and reference details, order at left...
5.	Vomiting 01/01/2001 - "Pre-treatment with yohimbine, MK-912 or MK-467 (alpha(2)-adrenoceptor antagonists) caused sudden and unexpected vomiting" Get all the results and reference details, order at left...
9 Diseases and 8 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Insulin (Novolin)
3.	Clonidine (ST 155)
4.	Yohimbine (Yocon)
5.	Idazoxan
6.	Guanfacine (Tenex)
7.	Norepinephrine (Noradrenaline)
8.	Dihydroxyphenylalanine (Dopa)
9.	BRL 44408
10.	L 659066
11 Drugs and Important Bio-Agents and 7 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>